universities admission office Bristol secures £45M to advance gene therapy treatment of chronic kidney diseases

universities admission office Bristol secures £45M to advance gene therapy treatment of chronic kidney diseases

https://www.bristol.ac.uk/media-library/sites/news/2018/april/kidney-home.jpgThe University of Bristol has secured a £45million deal to advance its groundbreaking gene therapy technology for chronic kidney diseases. The commitment, made by healthcare company Syncona Ltd to Bristol spin-out Purespring Therapeutics, aims to address a global unmet need for renal conditions in one of the largest single investments made to a new UK university biotech company.